

# FoxOs Cooperatively Regulate Diverse Pathways Governing Neural Stem Cell Homeostasis

Ji-hye Paik,<sup>1</sup> Zhihu Ding,<sup>1</sup> Rujuta Narurkar,<sup>1</sup> Shakti Ramkissoon,<sup>2</sup> Florian Muller,<sup>1</sup> Walid S. Kamoun,<sup>3</sup> Sung-Suk Chae,<sup>3</sup> Hongwu Zheng,<sup>1</sup> Haoqiang Ying,<sup>1</sup> Jed Mahoney,<sup>1</sup> David Hiller,<sup>4</sup> Shan Jiang,<sup>1</sup> Alexei Protopopov,<sup>1</sup> Wing H. Wong,<sup>4</sup> Lynda Chin,<sup>1</sup> Keith L. Ligon,<sup>2</sup> and Ronald A. DePinho<sup>1,\*</sup>

<sup>1</sup>Departments of Medical Oncology, Medicine, and Genetics, Belfer Institute for Applied Cancer Science

<sup>2</sup>Center for Molecular Oncologic Pathology, Department of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA

<sup>3</sup>Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

<sup>4</sup>Department of Statistics, Stanford University, Stanford, CA 94305, USA

\*Correspondence: ron\_depinho@dfci.harvard.edu

DOI 10.1016/j.stem.2009.09.013

## SUMMARY

The PI3K-AKT-FoxO pathway is integral to lifespan regulation in lower organisms and essential for the stability of long-lived cells in mammals. Here, we report the impact of combined FoxO1, 3, and 4 deficiencies on mammalian brain physiology with a particular emphasis on the study of the neural stem/progenitor cell (NSC) pool. We show that the FoxO family plays a prominent role in NSC proliferation and renewal. FoxO-deficient mice show initial increased brain size and proliferation of neural progenitor cells during early postnatal life, followed by precocious significant decline in the NSC pool and accompanying neurogenesis in adult brains. Mechanistically, integrated transcriptomic, promoter, and functional analyses of FoxO-deficient NSC cultures identified direct gene targets with known links to the regulation of human brain size and the control of cellular proliferation, differentiation, and oxidative defense. Thus, the FoxO family coordinately regulates diverse genes and pathways to govern key aspects of NSC homeostasis in the mammalian brain.

## INTRODUCTION

The PI3K-AKT-FoxO signaling pathway plays a central role in diverse physiological processes relevant to aging and cancer. This signaling axis translates extracellular cues into intracellular gene expression changes to maintain cellular homeostasis. In line with genetic studies in *C. elegans* and *D. melanogaster* revealing an epistatic relationship across PI3K-AKT-FoxO, the mammalian FoxO family of transcription factors (FoxO1, 3, and 4, hereafter referred collectively as FoxOs) also act as key downstream effectors of PI3K-AKT pathway and function to control many genes governing various cellular processes such as proliferation, survival, metabolism, differentiation, and oxidative

defense (reviewed in Greer and Brunet, 2005). Recent studies from our group have underscored that the mammalian FoxOs function redundantly to promote the stability of long-lived cells such as thymocytes and endothelial cells and to maintain hematopoietic stem cell (HSC) reserves that produce countless blood cells over a lifetime. To control these processes across these various systems, the FoxOs have been shown to regulate distinct sets of gene targets depending on cell type, tissue context, and developmental stage (Paik et al., 2007; Tothova et al., 2007).

The mammalian brain is a dynamic organ that maintains the capacity to generate new neurons as a function of advancing age and after brain injury. This regenerative capacity derives from resident neural stem cells (NSCs) that contribute directly to neurogenesis throughout development and adulthood. Processes including the proliferation, differentiation, and fate determination of NSCs and progenitor cells, and the survival, maturation, and integration of newborn neurons into existing neural circuits have been shown to be necessary steps in adult neurogenesis. NSCs reside within the ventricular zone of the embryonic neural tube and, in adult brain, primarily in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG). In adult mice, relatively quiescent NSCs give rise to transit-amplifying progenitor cells that rapidly divide and contribute to neuroblasts (Morshead et al., 1994; reviewed in Zhao et al., 2008). Newly generated neuroblasts in the SVZ migrate to become granule and periglomerular neurons in the olfactory bulb, and neurons born in the SGZ migrate into the granule cell layer of the DG and become dentate granule cells, contributing to the maintenance and reorganization of the existing circuitry and affecting memory and behavior (Imayoshi et al., 2008; reviewed in Zhao et al., 2008).

Recent studies have identified a number of pathways, including the PI3K-AKT, PTEN, and TSC, governing embryonic and tissue stem cell self-renewal, maintenance, and regenerative responses (Gan et al., 2008; Groszer et al., 2001, 2006; Paling et al., 2004; Yilmaz et al., 2006). Extracellular cues present within the stem cell niche include Wnt, Hedgehog, bone morphogenetic protein (BMP), fibroblast growth factor (FGF), epidermal growth factor (EGF), and the transforming growth factor (TGF $\beta$ ), all of which have been shown to affect self-renewal capacity both

in vivo and in vitro (Battista et al., 2006; Doetsch et al., 2002a; Jin et al., 2003; Palma et al., 2005; Reya et al., 2003). Furthermore, several studies have underscored the importance of finely tuned regulation of cell cycle/quiescence, apoptosis, and intracellular redox status in the maintenance and fate determination within tissue stem cell compartment (Cheng et al., 2000a, 2000b; Doetsch et al., 2002b; Ito et al., 2004, 2006; Kippin et al., 2005; Kozar et al., 2004; Malumbres et al., 2004; Yuan et al., 2004). The molecular mechanisms by which the PI3K-AKT pathway (and the FoxO family in particular) regulate NSC self-renewal, proliferation, and differentiation in the developing or mature brain are areas of active investigation.

On the basis of the fact that FoxOs had been reported to influence each of these processes in other systems (reviewed in Greer and Brunet, 2005), and the importance of the FoxOs in the maintenance of HSC reserves (Miyamoto et al., 2007; Tothova et al., 2007), and finally the highly cell type-specific nature of the FoxO action (Paik et al., 2007), we sought to gain an in-depth understanding of the specific functions of the FoxOs in the mammalian central nervous system (CNS) with an emphasis on the growth and renewal potential of neural stem and progenitor cells (hereafter referred to collectively as “NSC”). Here, an integrated computational, molecular, cellular, and organismal analysis has identified and validated FoxO direct targets and their linked pathways and biological processes that serve to regulate various aspects of NSC biology including proliferation, survival, renewal, and oxidative defense. This multilevel analysis establishes FoxOs as key molecules in processes central to NSC homeostasis and defines the genes through which the FoxOs execute their biological actions in this critical stem cell system.

## RESULTS

### FoxOs Constrain Proliferation and Sustain Renewal of NSCs


Immunohistochemical analysis of wild-type adult mouse brain shows that FoxO1 and 3 are broadly expressed in multiple cell types including neurons (NeuN<sup>+</sup>), astrocytes (GFAP<sup>+</sup>), and oligodendrocytes (Olig2<sup>+</sup>), in different locations as reported previously (Figures S1A and S1M–S1Q available online; Hoekman et al., 2006). In particular, we documented high levels of FoxO1 and 3 expression in the multipotent progenitors (Sox2<sup>+</sup>) of the SVZ in the forebrain and the SGZ in the hippocampus (Figures S1C, S1E, S1I, S1M, and S1N). In the embryonic brain (E15.5), FoxO1 and 3 also had broad and partially overlapping patterns of expression particularly within the NSC-rich ventricular zone (VZ). Within the VZ, FoxO1 expression is somewhat restricted with the highest level of expression noted in Nestin-positive radial glial progenitors of the dorso-medial wall of the VZ; in contrast, FoxO3 is expressed more broadly throughout all regions of the VZ examined (Figures S1J–S1L). As further evidence for their potential functional relevance in the NSC, we also detected high level expression of FoxO mRNA and proteins in NSC-containing neurospheres cultured from embryonic and postnatal brains (Figure S2). The prominent expression of FoxO1 and 3 in NSC-rich regions of the developing and adult brain, and FoxO1, 3, and 4 expression in cultured NSC-containing neurospheres from embryonic and adult brain prompted further study of the FoxO family in these cells.

To circumvent embryonic lethality associated with impaired vascular development because of broad FoxO1 deficiency (Hosaka et al., 2004), we utilized conditional knockout alleles of FoxO1, 3, and 4 (*FoxO1/3/4<sup>LoxP</sup>*) to achieve somatic inactivation of FoxO in the mouse brain. Here, we selected a particular *hGFAP-Cre* transgenic line that has been well documented in multiple published studies to be highly active in neural stem/progenitor cells (Figures S1G and S1H; Zheng et al., 2008; Zhuo et al., 2001; Lim et al., 2009) although it is also active in developing and mature astrocytes. Indeed, nearly complete deletion of FoxOs was observed in NSC-rich regions of adult brain, including SVZ, in *hGFAP-Cre: FoxO1/3/4<sup>LoxP</sup>* mice (Figures S1B, S1D, S1F, and S1I).

*FoxO1/3<sup>LoxP</sup>* allelic combinations with *hGFAP-Cre* showed significantly increased overall brain size (i.e., thickness of cortices and corpus callosum) and weight relative to *hGFAP-Cre*-negative controls that was evident at 12 weeks of age (Figure 1A; Figures S3B and S3C). The low expression of FoxO4 in these regions targeted by this particular *hGFAP-Cre* allele raised the possibility that the increased brain size of *hGFAP-Cre: FoxO1/3/4<sup>LoxP</sup>* mice was predominantly due to FoxO1 and FoxO3 deficiencies. Indeed, *hGFAP-Cre: FoxO4<sup>LoxP</sup>* mice, alone or in the triple knockout, exhibited a minimal effect on brain size consistent with its low expression (Figure S3B). Consistent with prominent FoxO1 and 3 coexpression patterns in vivo, combined FoxO1 and 3 deficiencies (*hGFAP-Cre: FoxO1/3/4<sup>LoxP</sup>*) had a more pronounced effect on brain size than individual FoxO1 or FoxO3 deficiency in the context of FoxO4 deficiency (*hGFAP-Cre: FoxO3/4<sup>LoxP</sup>* or *:FoxO1/4<sup>LoxP</sup>*). Notably across all of the genotypes, FoxO3 exerts the greatest phenotypic impact on brain size as observed in both conditional and germline knockout mice (Figure S3B; data not shown).

Histological inspection showed no apparent developmental abnormalities or alterations in brain cytoarchitecture prior to early adulthood (3 weeks of age) in any of the genotype combinations (Figure S3A). At 10 days postnatally, the number of both neurons and glia increased in cerebral cortex of FoxO-null brain (NeuN<sup>+</sup>, 4486 versus 5024; S100<sup>+</sup>, 301 versus 402,  $p < 0.1$ ) where almost all the cells underwent Cre-mediated recombination as measured by reporter activity (Figure 1B). At approximately 15 weeks of age, mild ventricular enlargement became obvious in all three FoxO-deficient brains (Figures S4A and S4B). The above coexpression profiles, coupled with high functional redundancy among FoxO family members in the brain (this study) and other tissues (Paik et al., 2007), prompted us to focus our detailed phenotypic analyses on the triply null FoxO brains (*GFAP-Cre: FoxO1/3/4<sup>LoxP</sup>* hereafter referred to as “null” and *FoxO1/3/4<sup>LoxP</sup>* as “WT”) for detailed CNS and NSC analyses.

To understand the basis for increased brain size, we examined cell proliferation and size as a function of FoxO status in the young brain (P8). FoxO deletion was nearly complete in Sox2<sup>-</sup>, NeuN<sup>-</sup>, GFAP<sup>-</sup>, or Olig2<sup>-</sup> positive cell types in the FoxO-null brain with the exception of a few anatomical regions (Figures S1I and S1O–S1Q). A prominent increase in cell cycle re-entry (i.e., Ki67/BrdU/Sox2 triple-positive cells) among BrdU-labeled population was evident in the NSC-rich regions of the SVZ in FoxO-null brain (Figure 1C; 18.85% versus 10.82%,  $p < 0.01$ ). In contrast, detailed morphometric analyses showed no change in the soma size of neurons or astrocytes in FoxO-null brains



**Figure 1. Increased Brain Size and Cycling of NSCs in FoxO-Null Mice and Their Derived Culture**

(A) Representative photograph of brains from 20-week-old FoxO WT (left) and null (right) mice.

(B) The number of glia and neurons was estimated by counting S100 or NeuN-positive cells in the cerebral cortex of 10-day-old FoxO WT (black squares) and null (gray squares) pups. There are more S100 or NeuN-positive cells in FoxO-null brain compared with the control ( $*p < 0.1$ ). \*\* indicates the region where S100<sup>+</sup> and NeuN<sup>+</sup> cells were scored. *hGFAP-cre* mice were crossed with *ROSA26R* mice, where Cre-mediated recombination drives the constitutive expression of the  $\beta$ -galactosidase. X-gal-staining-positive cells are shown in blue.

(C) Increase in cell cycle re-entry of FoxO-null SVZ cells. Young mice (P8) were single-pulse labeled with BrdU 24 hr prior to the sacrifice and brain sections were stained for BrdU (red), Ki67 (green), and Sox2 (cyan). The fraction of Sox2-positive cells re-entered cell cycle (open arrow, BrdU<sup>+</sup>/Ki67<sup>+</sup>/Sox2<sup>+</sup> triple positive) increased in FoxO-null SVZ and that of no longer dividing (filled arrow, BrdU<sup>+</sup>/Ki67<sup>-</sup>/Sox2<sup>+</sup>) is higher in WT SVZ. Percent mean  $\pm$  SD of Ki67<sup>+</sup> cells from BrdU<sup>+</sup>/Sox2<sup>+</sup> cells from 10 WT and 6 FoxO-null mice is shown ( $*p < 0.001$  by two-tail t test). Scale bar represents 40  $\mu$ m.

(D) Ki67-positive NSCs of FoxO WT and null cultures ( $n = 5, P2$ ). Scale bar represents 20  $\mu$ m.


(Figures S5A–S5C). Of note, we detected the presence of hypertrophic astrocytes only in older FoxO-null animals (>32 week) and in vitro differentiated culture from late-passage FoxO-null NSCs (Figures S5D and S5E). Together, these observations suggest that FoxOs function to constrain the cycling of NSCs and/or progenitor cells, but not their size, an observation in line with *Drosophila* FoxO control of cell proliferation but not cell size (Puig et al., 2003).

Given that the *hGFAP-Cre* transgene directs FoxO deletion in NSCs as well as other CNS lineages (Figures S10–S1Q; Zhuo et al., 2001), we sought to further define the specific impact of FoxO deficiency on NSC proliferation and renewal by using

well-established cell culture-based approaches. Ki67 expression (Figure 1D) and population doubling (Figure 2A) in NSC cultures revealed that early-passage (P2) FoxO-null NSC cultures had increased proliferation. Thus, FoxOs constrain the proliferative activity of NSCs and/or progenitor cells in the young adult brain and in early-passage cell cultures.

#### FoxO-Deficient Brains Exhibit Precocious NSC Depletion

Although increased proliferation of FoxO-null NSC cultures was observed initially, continued passage in culture showed exhaustion of neurosphere formation potential with accompanying



**Figure 2. Suppression of ROS Does Not Inhibit Hyperproliferation of FoxO-Null NSCs**

(A) Proliferation of FoxO WT (blue line) and null (red line) NSCs (*Rosa26-CreERT2*<sup>+</sup> and *-FoxO1/3/4<sup>+/L</sup>*, respectively) over the eight passages after 4OHT treatment is plotted. y axis indicates log<sub>2</sub> (cells counted after 5 days in culture/cells seeded). Result is representative of three independent cultures (\*p = 0.0047; \*\*p = 0.015).

(B) NAC treatment does not attenuate proliferation of FoxO-null NSCs. P2 NSCs were treated with up to 5 mM NAC for 24 hr and fraction of BrdU<sup>+</sup> cells was plotted. Scale bar represents 30 μm.

(C) NAC treatment does not inhibit increased cycling of Sox2<sup>+</sup> cells in 8-day-old FoxO-null brain. 3-day-old FoxO-null mice were treated with NAC for 5 days before sacrificed. Percent mean ± SD of Ki67<sup>+</sup> cells from BrdU<sup>+</sup>/Sox2<sup>+</sup> cells from NAC (n = 6) or water (n = 6) -treated FoxO-null mice is shown (p = 0.08 by two-tail t test).


(D) Increased apoptosis in late-passage (P8) FoxO-null NSCs was reversed by 1 mM NAC treatment. No apparent changes in apoptosis were observed in early passage (P2). Cleaved caspase3-staining-positive cells were scored and normalized by total number of DAPI-positive cells. Fractions of apoptotic cells are plotted. \*p = 0.017, \*\*p = 0.021.

decreased proliferation and marginally increased apoptosis (Figures 2A and 2D; note the use of single-cell clonogenic assays in Figure 3D, BrdU). This progressive renewal defect in cell culture prompted closer examination of NSC reserves in vivo. Staining brain sections with antibodies to Sox2, a marker for NSCs, revealed that 15-week-old FoxO-null brain shows a significant 25% decline in Sox2-positive cells in the SVZ (Figure 3A; gray bars, 1 versus 0.757, p = 0.004). In addition to the decrease in Sox2-positive SVZ cells to levels well below FoxO WT brains, there was an accompanying decline in doublecortin (DCX, Figure 3B; gray bars, 1 versus 0.283, p = 0.0039) and Ki67 (Figure 3B; gray bars, 1 versus 0.717, p = 0.026) -positive cells and a decline in the number of newborn neurons in the olfactory

bulb to numbers below those in FoxO WT brains (1.76% versus 0.92%, p = 0.018; Figure S4C). Accompanying this decline in NSC and neurogenic populations, the FoxO-null brain shows consistent and progressive ventricular dilation and thinning of the lateral ventricular wall and SVZ (Figures S4A and S4B; 100% versus 751.1%, p = 0.011). These pathological changes were most evident in more aged brains, while absent in the developing brain, suggesting that the loss of FoxO function in the embryonic and adult brain together impacts most prominently processes controlling the size and function of NSC pool in postnatal mouse brain (Figures 3A and 3B; black bars).

The in vivo marker patterns suggesting a decline in NSC/progenitor cell populations prompted us to perform a series





**Figure 3. FoxO-Deficient Brain Exhibits Decrease in NSC Reserve and Neurogenesis**

(A) Decreased Sox2-positive NSCs in 32-week-old FoxO-null (right) brain. Scale bar represents 50 μm.

(B) Decline in neural progenitor proliferation and neurogenesis measured by Ki67 and DCX expression in SVZ of lateral wall from 32-week-old FoxO-null mice (right). 200× microscopic field of comparable region from WT littermate control mouse is shown (left). Insets are higher magnification view of boxed regions. Scale bar represents 50 μm.


(A and B) Graphs at right: Sox2 (A), DCX (B), Ki67 (B) expression levels in young (8-week-old, black squares) and relatively old (15- to 32-week-old, gray squares) mice SVZ were measured by laser scanning and plotted (4 pairs; \*p = 0.004, \*\*p = 0.0039, †p = 0.026, by two-tail paired t test).

(C and D) Decreased self-renewal capacity of NSCs derived from 18- to 22-week-old FoxO-null mice (C) and acutely deleted for FoxOs in vitro (D). For conditional deletion, NSCs were isolated from SVZ of 4-week-old *Rosa26-CreERT2*<sup>+</sup> (null) or <sup>-</sup>(WT) *FoxO1/3/4<sup>L/L</sup>* mice and treated with 400 nM 4OHT prior to the assay. Results are representative of three independent experiments with two primary cultures. Both average diameters for all the neurospheres and for multipotential ones are shown as mean ± SD. Proliferation index is shown as fraction of BrdU incorporation from triplicate cultures in two independent experiments. §p = 0.0043, #p < 0.0001, \*p = 0.01, \*\*p = 0.03, †p = 0.06, ‡p = 0.096 by two-tail t test. Scale bars represent 100 μm.

of complementary cell culture-based quantitative studies to measure the self-renewal capacity of cells derived from the fore-brain of adult FoxO-null mice. The percentage of cultured cells from adult FoxO-null mice (18- to 22-week-old) capable of forming secondary multipotent neurospheres was lower than cells derived from WT littermate controls (Figure 3C; 3.6% versus 1.3%). Specifically, FoxO-null cultures exhibited significant reduction in proliferation by BrdU incorporation (Figure 3C; 0.2 versus 0.07, p = 0.03) and in average diameter of neurospheres (Figure 3C; Figure S6A; 90.3 μm versus 61.4 μm, p = 0.0043). Together, these findings suggest that FoxOs regulate the proliferative and self-renewal potential of NSCs and that the loss of FoxO function results in the progressive decline of NSC number.

It is important to emphasize that our experimental strategy deletes FoxO in NSCs and other CNS lineages, thus potentially affecting NSC biology directly and/or indirectly via alterations in the surrounding microenvironment. Thus, we sought to assess

whether deletion of FoxO upon in vitro isolation and culturing would produce the same phenotypes observed in NSC cultures where FoxOs were deleted in vivo. To that end, by using single-cell clonogenic assays, we tested the self-renewal capacity of NSCs from SVZ of young adult mice (4-week-old) that was subjected to acute FoxO deletion in vitro with an inducible Cre system. Consistent with in vivo findings, acute in vitro deletion of all three FoxOs with the transiently 4OHT-activated *Rosa26-CreERT2* system resulted in a same decrease in self-renewal capacity (Figure 3D; 3.9% versus 1.9%, p = 0.096) along with decreased average diameter of neurospheres (Figure 3D; Figure S6B; 157.8 μm versus 98.6 μm, p < 0.0001) and proliferation as per BrdU incorporation (Figure 3D; 0.38 versus 0.16, p = 0.010). Furthermore, an accompanying article shows that deletion of FoxO3 alone in the brain via an independent Cre-deletor transgenic line, *Nestin-Cre*, which allows deletion in NSCs (as well as other cell types), also produces similar decline in NSC number both in vivo and in vitro (Renault et al., 2009, this issue). The concordant phenotypes in vitro and in vivo, as well as across multiple different experimental systems support the view that precocious depletion of NSCs in FoxO-deficient brain is, at least in part, a cell-autonomous phenomenon. Thus, we



**Figure 4. Regulation of NSC Self-Renewal by FoxO through Controlling Intracellular ROS Level**

(A–D) Accumulation of intracellular ROS in FoxO-null NSCs (P7) is measured by DCF-DA staining and flow cytometry. Numbers indicate mean intensity level (A) and percent of total event above the threshold (C). Both NAC treatment (1 mM) and enforced expression of SESN3 normalized and suppressed ROS level (A, C) and partially rescued self renewal in FoxO-null NSCs (B, D). Expression of SESN3-v5 in NSCs is shown below by immunoblotting of v5 epitope (C). (B and D) Representative images of cultured neurospheres from two independent experiments are shown. Both average diameters for all the neurospheres and for multipotential ones are shown as mean  $\pm$  SD. Proliferation index is shown as fraction of BrdU incorporation from triplicate cultures in two independent experiments. \* $p < 0.01$ , † $p < 0.05$  by ANOVA with Bonferroni's post test. Scale bars represent 100  $\mu\text{m}$ .

propose that the FoxOs function to support NSC homeostasis in vivo, perhaps by preventing the rapid amplification of progenitors and the consequent exhaustion of the relatively quiescent NSCs.

#### FoxO-Deficient NSCs Have Increased ROS and Decreased Self-Renewal Potential

We have previously reported that loss of all three FoxOs in HSCs results in decreased expression of ROS-detoxifying enzymes,  $\beta$ -catalase, and manganese superoxide dismutase (MnSOD), and that increased intracellular ROS levels in FoxO-null HSCs are causally linked to enhanced G0 exit and increased apoptosis, resulting in progressive depletion of HSC reserves

(Tothova et al., 2007). To determine whether altered regulation of genes involved in oxidative defense contribute to these similar defects in NSCs, we performed the DCF-DA ROS measurement assay, which showed an increase in intracellular ROS levels in FoxO-null NSCs relative to WT control cultures (Figure 4A; mean intensity level of 2904 versus 533). However, contrary to the HSC findings of altered  $\beta$ -catalase and MnSOD expression, the FoxO NSC transcriptome instead shows prominent dysregulation of a distinct set of ROS detoxifying enzymes including peroxiredoxin, glutathione peroxidase1, and sestrin3 (SESN3) (Table S3). To examine whether ROS accumulation in NSC also causally contributes to the biphasic phenotypes of hyperproliferation and/or long-term exhaustion, we reduced ROS

levels either by treatment with the antioxidant N-acetyl cysteine (NAC) or by enforcing the expression of SESN3, a cysteine sulfenic acid reductase that reduces peroxiredoxins. Normalized (by NAC) or reduced (by enforced SESN3) intracellular ROS levels (Figures 4A and 4C) enhanced the self-renewal capacity of FoxO-null NSC cultures as measured by neurosphere formation assay (Figures 4B and 4D; 0.9% versus 2.6% and 1.4% versus 3.0%, respectively,  $p < 0.05$ ). In particular, the late passage (P7) of NAC-treated or SESN3-transduced FoxO-null NSCs showed improved proliferation as measured by BrdU incorporation (Figures 4B and 4D; 0.09 versus 0.21,  $p < 0.01$ ), decreased apoptosis (Figure 2D), and increased overall neurosphere diameter (Figures S6C and S6D).

In contrast, in the early-passage FoxO-null NSCs, NAC treatment (up to 5 mM) had no effect on the transient hyperproliferation phenotype nor did it affect the proliferation of FoxO WT NSCs (Figure 2B; con versus NAC, 0.295 versus 0.294,  $p = 0.966$ , P2). Furthermore, *in vivo* administration of NAC did not suppress increased cycling of Sox2<sup>+</sup> cells in postnatal FoxO-null brains (Figure 2C; NAC versus PBS, 21.3% versus 18.9%,  $p > 0.05$ ), supporting the view that increased ROS plays no discernable causal role in increased proliferation of FoxO-null NSCs in the young postnatal brain. Together, these studies suggest that, while FoxO-directed regulation of intracellular ROS level plays an important role in NSC self-renewal capacity, it plays no discernable role in controlling the proliferation activity of the NSCs.

### Identification of FoxO Transcriptional Targets Regulating NSC Biology

The lack of complete rescue of the self-renewal defects, even with normalization of ROS by NAC treatment, pointed to additional FoxO-regulated pathways governing NSC biology. To identify functionally relevant FoxO direct gene targets and their linked physiological actions, we conducted unbiased transcriptomic profiles in WT and FoxO-null NSCs and *in silico* promoter analysis followed by confirmatory biochemical and biological validation studies.

Transcriptomic analysis of multiple independent FoxO WT and null early-passage neurosphere cultures revealed differential regulation of 3425 genes by FoxOs as determined by two independent statistical methods (Table S1). Among these are known effectors of FoxO and their family members (e.g., Cyclin D1, Inhibitor of DNA binding 1 and 2, and Polo-like kinase 2) (Alvarez et al., 2001; Birkenkamp et al., 2007; Schmidt et al., 2002) as well as many potential novel FoxO targets that relate well to our biological observations including cell cycle (e.g., G two and S phase expressed1, Cdk inhibitor 1C, Sal like2) and glial differentiation (e.g., Hes5, Sox10, Myelin basic protein, Plp1, Cystatin C) and that functionally interact with FoxOs (e.g., FoxG1, Sirt2) (Seoane et al., 2004; Wang et al., 2007). Notably, the NSC FoxO transcriptome demonstrates minimal overlap with other cell types including HSCs—a finding in line with previous observations that the FoxOs regulate their targets in a highly cell type-specific manner (i.e., the FoxO transcriptomes of HSC, thymocytes, or endothelial cells show minimal overlap) (Paik et al., 2007; Tothova et al., 2007). Nevertheless, despite these cell type-specific gene target differences, knowledge-based pathway analysis showed convergent regulation of well-known FoxO


networks such as IGF-1/PI3K/PTEN, cell cycle, and metabolic pathways (data not shown).

Next, we sought to identify direct FoxO targets in order to gain further insights into FoxO's role in NSC biology. To that end, a systematic and validated *in silico* promoter analysis approach (Paik et al., 2007) was used to identify evolutionarily conserved FoxO consensus binding elements (BE) in the regulatory regions of the top 186 genes (144 downregulated, 42 upregulated in FoxO null) that show the most significant expression differentials (SAM > 2; and see Experimental Procedures) (Table S2). To search for FoxO BE, each gene region was surveyed from 10 kb up- or downstream of the transcription start or end site. By this approach, 96 of the 186 genes were found to contain putative conserved FoxO BEs. 18 of the 96 genes from diverse gene ontology categories were selected and their direct regulation by FoxOs was tested on several levels including (1) differential mRNA expression by RT-qPCR in FoxO null versus WT, (2) adenoviral-transduced expression of active form of FoxO1 and 3 (CA-FoxO1/3) (Figure S8A), (3) documentation of physical binding of FoxOs on predicted BE by chromatin immunoprecipitation (ChIP) (Figure S8B), and (4) confirmation of target gene differential expression by RISH in FoxO WT and null embryonic brains (data not shown). Of the 18 putative targets tested, these integrated analyses and highly stringent criteria confirmed 8 bona fide novel FoxO direct targets (*Aspm*, *Tmeff2*, *Sirt2*, *Kitl*, *Tspan7*, *Sfrp1/2*, and *Sost*). Several of these FoxO targets have plausible, albeit unexplored, links to NSC biology prompting further functional study.

### FoxOs Directly Repress ASPM Expression in the Regulation of NSC Proliferation

The FoxO NSC transcriptome and pathway analyses were notable for alterations in proliferation and differentiation networks, the imbalance of which may provide an explanation for the enlarged brain phenotype and the abnormal cycling that could ultimately lead to exhaustion of NSCs. For example, there is increased expression of cyclins (*Ccn A2, B1, B2, C, D1, D3, E1, G1, T2*) and cyclin-dependent kinases (*Cdk 2, 4, 7*) and decrease in specific cyclin-dependent kinase inhibitors (*p57<sup>KIP2</sup>*) that correlate well with observed short-term hyperproliferation phenotype in FoxO-null NSCs (Table S1). A notable cell cycle gene that may relate to the FoxO-null brain size phenotype is *Aspm* (abnormal spindle-like microcephaly-associated) gene. In humans, *ASPM* is a determinant of human cerebral cortical size, i.e., individuals with *ASPM* germline loss-of-function mutations show primary microcephaly (Bond et al., 2002). *ASPM* expression has been shown to be required for symmetric, proliferative divisions of neural stem/progenitor cells of the mammalian brain (Fish et al., 2006; Horvath et al., 2006).

Consistent with the relevance of the FoxO-*ASPM* link in NSC biology, we observed (1) significantly increased *Aspm* mRNA levels in FoxO-null NSCs by RT-qPCR (Figure 5A), (2) increased *ASPM* protein and mRNA in NSC-rich regions of FoxO-null embryonic brains (Figure 5B, RISH, not shown), and (3) increased *ASPM*-positive cells in FoxO-null NSC cultures (Figure 5C). Second, *in silico* methods (Paik et al., 2007) identified evolutionarily conserved FoxO BEs in the *Aspm* promoter which were confirmed to bind FoxO by ChIP assay in NSCs (Figure 5D). Third, on the functional level, *Aspm* shRNA-mediated knockdown (two



**Figure 5. FoxO-Dependent Expression of ASPM Regulates NSC Proliferation**

(A and B) Differential expression of *Aspm* mRNA in FoxO WT and null embryonic NSCs measured by RT-qPCR (A) and protein by IHC analysis (B) on FoxO WT and null E15.5 embryonic brain. Scale bar represents 50 μm.  
 (C) Number of mitotic spindle-localized ASPM-positive NSCs in FoxO WT and null cultures. Representative images are shown below. Scale bar represents 10 μm.  
 (D) The *Aspm* promoter is occupied by both FoxO1 and FoxO3 in NSCs. On the schematic representation of the *Aspm* promoter, FoxO binding sites are depicted relative to the +1 transcriptional start site. ChIP analysis of NSCs with FoxO1, FoxO3, IgG, or PolII antibodies. Primers were designed to encompass the FoxO binding sites.  
 (E) Knockdown of *Aspm* by shRNAs in FoxO-null NSCs. *Aspm* mRNA level was measured by RT-qPCR after 48 hr of sh*Aspm* lentiviral transduction.  
 (F and G) Decreased proliferative potential in *Aspm* knockdown NSCs was measured by BrdU incorporation assay (F) and neurosphere formation (G). \**p* < 0.01, #*p* < 0.05 by ANOVA with Bonferroni's post test. NA, not analyzed, NT, nontargeting control shRNA-infected culture. Scale bars represent 100 μm.

independent hairpins) resulted in a profound decrease in proliferation of FoxO-null NSCs (Figures 5E–5G; 0.41 versus 0.06 and 0.11 for BrdU incorporation, *p* < 0.01). Notably, NSCs with *Aspm* knockdown exhibited significant decrease in size of neurospheres and self-renewal potential in single-cell clonogenic assays (Figure 5G; Figure S6E; 95.4 μm versus 48.2 μm and 54.1 μm in average diameter, *p* < 0.01 and 1.6% versus 0 and

0.3% for self-renewal, *p* < 0.05), a phenotype associated with increased cell cycle exit and differentiation (data not shown). Thus, *Aspm* is a physiologically relevant target of FoxO in the regulation of proliferation and the renewal of NSCs. We propose that the derepression of *Aspm* in FoxO-null NSCs contributes to the observed short-term hyperproliferative defects in this progenitor compartment and the enlarged brain phenotype.



### FoxOs Attenuate Wnt Signaling in NSCs

The FoxO transcriptome is also notable for regulatory factors of the Wnt pathway, a pathway whose stringent control is required for the long-term homeostasis of many tissue stem cells. In particular, there was significant downregulation of soluble frizzled receptors (*Sfrp*) 1 and 2 as well as sclerostin (*Sost*) in FoxO-null NSC transcriptome (Table S1). First, as above, the link between FoxO status and these factors was confirmed by their higher mRNA expression in FoxO WT relative to FoxO-null NSCs (Figure 6A) and by the presence of conserved ChIP-validated FoxO binding elements in their promoters (Figure 6B). Second, enforced expression of constitutively active (CA)-FoxO1 or 3 can induce expression of *Sfrp1/2* and *Sost* in FoxO-null NSCs (Figure S8A). Third, because these soluble factors act as an antagonist for Wnt ligands, we utilized the TOFlash reporter system to measure the activity of canonical Wnt pathway in our system. Addition of Wnt3a, but not Wnt5a, induced TCF/Lef/ $\beta$ -catenin-dependent transcriptional activity, confirming the specificity of reporter activity responsive to the canonical Wnt signaling. This response is reproducibly enhanced in FoxO-null NSCs (Figure 6C). Conversely, enforced expression of CA-FoxO1 or 3 suppressed reporter activity (i.e., dampened Wnt signaling) (Figure 6D). In agreement with the reporter assays, the expression of the targets dependent on Wnt signaling including *Cyclin D2* and *Myc* were upregulated in FoxO-null NSCs (Figure S7A). Fourth, RNAi-mediated knockdown of sFRP1/2 and SOST was performed to examine the role of these factors in FoxO-mediated repression of Wnt signaling in NSCs. Combined knockdown of all three sFRP1/2 and SOST resulted in a 1.5-fold increase in Wnt3a-induced reporter activity and this increase was completely reversed by the addition of recombinant sFRP1/2 and SOST (Figure S7B; Figure 6E). Knockdown of individual factors did not cause appreciable differences in Wnt3a-induced reporter activity (data not shown), suggesting that these novel FoxO targets act cooperatively as soluble inhibitors of the Wnt pathway to repress Wnt signaling in NSCs.

Finally, we examined the biological impact of FoxO-repressed Wnt signaling on NSC proliferation. Exogenous Wnt3a treatment can induce a strong proliferative response in NSCs, and correspondingly, both FoxO-null and sFRP1/2 and SOST knockdown NSCs showed increased basal proliferation that was significantly inhibited by the addition of sFRP1/2 and SOST (Figure 6F). However, it is important to note that the Wnt3a-induced proliferative response is short lived and is followed by substantial decline in number of cycling cells, resembling the growth kinetics of FoxO-null NSC culture (Figure 6G). These observations further reinforce the cross talk between FoxO and Wnt signaling pathways in NSCs and the importance of finely tuned Wnt pathway activation in the long-term homeostasis of NSCs.

### DISCUSSION


In this study, an integrated molecular, cellular, and organismal analysis has established FoxOs as essential regulators of genes governing processes central to NSC biology (Figure 7). Disruption of these FoxO-dependent homeostatic processes in the mouse brain leads to initial deregulated NSC proliferation followed by a decline in NSC pool and accompanying neurogenesis

that is evident only in adult mice. The abnormal proliferation kinetics of NSCs in vitro and in vivo and the enlarged brains in FoxO-deficient brains establishes a role for FoxOs in the enforcement of NSC quiescence and control of NSC self-renewal. Mechanistically, a combined transcriptomic, computational, and biochemical analyses have identified a diverse set of direct functional targets and linked pathways through which FoxO directly executes its complex actions on NSCs and brain physiology.

Gradual depletion of NSCs in FoxO-null animals might be explained by a cell-autonomous role of FoxOs in regulating adult self-renewal potential. Alternatively, increased cell cycling during the development and establishment of NSC pool in the FoxO-null brain may lead to later decline in their number by intrinsic mechanism to adjust the size of stem cell pool within the niche. Despite the reinforcing parallel findings of our in vitro analyses showing an impact of FoxO deletion on NSC biology, it is possible that some of the NSC phenotypes derive in part from the broad deletion of FoxOs in cellular compartments other than the NSCs in the adult brain. However, it is worth noting that neuron-specific deletion of FoxOs (*Syn-Cre: FoxO1/3/4<sup>Lo/Lo</sup>*) is not accompanied by NSC abnormalities (data not shown). Nevertheless, we acknowledge that specific deletion of FoxOs only in mature astrocytes or only in adult NSCs will be needed to distinguish whether FoxOs exert their actions on NSC homeostasis via altered astrocyte support functions or by acting in NSCs. Our validated collection of FoxO targets establishes strong evidence that FoxO regulates ROS detoxification, Wnt signaling, cell cycle, and differentiation processes, which collectively serve to fine-tune the balance of growth, survival, and differentiation needed to achieve the regulation of NSCs throughout life (Figure 7).


The precocious decline in the NSC pool and neurogenesis in FoxO-null mice at 6 months of age indicates that FoxOs are important regulators of NSC function and renewal under physiological conditions in the brain. Consistent with functional redundancy among FoxOs in other tissues (Paik et al., 2007), the single and double FoxO-null brains show overtly normal patterns of neurogenesis through mid-adulthood (F.M. and R.A.D., unpublished observations). However, we also acknowledge that it remains possible that single (particularly FoxO3) FoxO-null mice may also experience more subtle decline in CNS function. Indeed, the accompanying study by Renault et al. (2009) demonstrates that lack of FoxO3 alone in the brain is sufficient to cause a defect in NSC number in vivo, a result suggesting a dominant role of FoxO3 relative to other FoxO family member in the brain.

That FoxO deficiency leads to transient increase in cycling cells is not unanticipated based on previous studies with other PI3K pathway components wherein loss of the negative regulator PTEN was shown to result in sustained proliferative potential of NSCs (Groszer et al., 2001, 2006). In contrast, the FoxO-null NSC/progenitor proliferation is distinct from that of PTEN-null NSCs in that it does not show sustained increased proliferation. When viewed through the multiple mechanistic findings of our study, we speculate that increased proliferation and ultimate precocious decline of NSCs and associated neurogenesis results from the combined impact of loss of fine-tuned cell cycle/quiescence control by dysregulation of



**Figure 6. FoxOs Negatively Regulate Wnt Signaling in NSCs**

(A) Expression of soluble antagonists of Wnt. Differential expression of *Sfrp1/2* and *Sost* mRNA in FoxO WT and null embryonic NSCs measured by RT-qPCR. (B) Promoters for *Sfrp1/2* and *Sost* are occupied by both FoxO1 and FoxO3 in NSCs. On the schematic representation of the promoter FoxO binding sites are depicted relative to the +1 transcriptional start site. ChIP analysis of NSCs with FoxO1, FoxO3, IgG, or PolII antibodies. Quantification of ChIP analysis on each promoter was assessed by RT-qPCR analysis. (C) Wnt3a-induced canonical Wnt signaling is measured by TOFlash reporter assay. Note enhanced signal in FoxO-null (gray squares) NSCs compared to WT (black squares). \* $p = 0.08053$ . (D) Attenuated Wnt3a-dependent canonical signaling by constitutively active FoxOs. CA1, CA3; FoxO1-ADA and FoxO3-AAA mutant, respectively. \* $p < 0.1$ . (E) Enhanced canonical signaling in *Sfrp1/2* and *Sost* knockdown NSCs (black squares) compared to WT (gray squares) is reversed by the addition of soluble sFRP1/2 and SOST (500 ng/ml). \* $p = 0.068$ ; \*\* $p < 0.005$ . (F) Exogenously added sFRP1/2 and SOST (500 ng/ml) reversed increased proliferation of FoxO-null NSCs. Wnt3a, 50 ng/ml of recombinant wnt3a was added for 24 hr. KD, 72 hr after knockdown by siRNAs for *Sfrp1/2* and *Sost*. Fractions of Ki67-positive nuclei are plotted. (G) Decreased long-term proliferation potential of NSCs by Wnt3a stimulation (100 ng/ml). y axis indicates  $\log_2$  (cells counted after 5 days in culture/cells seeded). Lines in red, FoxO null; blue, WT; yellow, Wnt3a-treated. \* $p = 0.0041$ ; \*\* $p < 0.01$ ; # $p = 0.0169$ .



**Figure 7. Model for FoxO-Dependent Regulation of NSCs**

FoxOs control NSC biology at multiple levels. FoxOs (A) negatively regulate G0 exit of NSCs and keep their quiescence within the niche, (B) support their long-term self-renewal activity, (C) constrain proliferation of lineage-committed neural progenitors, and (D) contribute to continued neurogenesis.

FoxOs engage the Wnt pathway on many levels to ensure a tight regulation of NSCs. We observe that enhanced Wnt pathway activity in FoxO-null NSCs leads to an acute short-term increase in their proliferation. Although the ensuing depletion of long-term self-renewal potency may relate to the dominance of other dysregulated pathways (see below), hyperactivity of Wnt signaling could paradoxically contribute to this decline as well. This possibility derives from the mechanistic analysis of the accelerated aging phenotype of *klotho*-deficient mice, a mutant mouse manifesting augmented Wnt signaling (Liu et al., 2007). As

exemplified in this study, loss of soluble antagonist for Wnt leads to cellular senescence caused by continuous Wnt signaling contributing to suppression of the number of stem/progenitor cells. Furthermore, consistent with a possible role of elevated Wnt signaling in stem cell maintenance, addition of Wnt has been shown to convert myogenic progenitor culture into fibrogenic lineage (Brack et al., 2007). Thus, whereas Wnt signaling is clearly essential for tissue stem cell renewal, the loss of finely tuned Wnt pathway activity in a narrow window in the FoxO-null NSCs could contribute to the defective maintenance via the collective impact of aberrant proliferation activity and presumably altered cell fate.

In summary, this study shows that the mammalian FoxOs have evolved to serve as longevity tumor suppressors designed primarily to maintain the homeostasis and the integrity of long-lived cells including tissue stem cell reserves. This contrasts with other tumor suppressors (e.g., *p16<sup>Ink4a</sup>*) that appear to suppress cancer at the cost of tissue-resident stem cells and therefore may contribute to decreased regenerative potential during the aging process (Krishnamurthy et al., 2006; Molofsky et al., 2006). The impact of FoxO activity on the CNS health under aging and stress, especially how FoxOs regulate NSCs in the aging brain, may prove useful for defining strategies to modulate regenerative response in the setting of acute brain injury or long-term degenerative conditions. Specifically, such insights may inform the development of drugs targeting pathways that may impair or improve CNS health in aging, neurodegenerative diseases, and injury states including those associated with medical treatments such as cancer chemo/radiation therapy.

#### EXPERIMENTAL PROCEDURES

##### Generation of Mice

All experimental and control animals were littermates or age matched. An *hGFAP-Cre<sup>+</sup>* male was mated with a *FoxO1<sup>L/L</sup>*; *FoxO3<sup>L/L</sup>*; *FoxO4<sup>L/L</sup>* (*FoxO1/3/4<sup>L/L</sup>*) female, and the progeny were then crossed with *FoxO1/3/4<sup>L/L</sup>* mice.

molecules such as the *p57<sup>KIP2</sup>* cell cycle inhibitor, ASPM, and WNT dampeners, among others. Beyond cell cycle regulation, it is possible that altered lineage commitment may also contribute to a decline in neurogenesis as indicated by the fact that the FoxO-null transcriptome shows changes of key developmental regulators (J.-h.P. and R.A.D., unpublished), a finding in line with previously reported role for FoxOs in cellular fate determination observed in myogenesis and hematopoiesis (Hu et al., 2008; Kitamura et al., 2007; Tothova et al., 2007). Thus, the FoxOs appear to regulate many cellular processes that require fine regulation to maintain the right balance of proliferation, survival, and cell fate commitment decisions in tissue stem cell pools, while responding to the regenerative needs of tissues throughout life (Figure 7).

Our analysis of the FoxO-null NSC transcriptome, along with analogous studies in the HSCs, confirm that FoxOs have conserved roles across different stem cell compartments via regulation of distinct lineage-specific sets of genes governing proliferation and intracellular ROS levels. However, relative to FoxO function in the HSCs (Tothova et al., 2007), this report establishes that its function in the NSCs shows a greater diversity of activities and pathway engagement. For example, the finding of *Aspm* as a direct target of FoxOs in NSCs is notable given the hypothetical role of ASPM as one of the genetic determinants underlying the positive selection in cerebral cortical size across different species (Bond et al., 2002). Significantly, ASPM deficiency was discovered to be the basis for a human genetic disorder characterized by microcephaly, which presents with reduced neurogenesis. Our findings that *Aspm* is one of the major targets of FoxOs and its knockdown limits expansion of the FoxO-null NSC cultures suggests that ASPM contributes to increased FoxO-null brain size phenotype via its known activities in the control of neural progenitor cell biology (Fish et al., 2006).

Our identification of *Sfrp1/2* and *Sost* as direct targets of FoxOs also supports the view that the FoxOs regulate NSC cellular responses to the extracellular signals via a coordinated regulation of specific target genes. Here, we establish that

The resulting offspring were intercrossed to generate mice of the desired genotypes. For the mapping of Cre activity, *hGFAP-Cre*<sup>+</sup> mouse was bred with ROSA26R reporter mouse (Soriano, 1999) and X-gal staining was performed to locate cells expressed Cre. For in vitro deletion of FoxOs, embryonic or adult NSCs were isolated from *Rosa26-CreERT2*<sup>+</sup> (kindly provided by Anton Berns, The Netherlands Cancer Institute, Amsterdam, The Netherlands);-*FoxO1/3/4*<sup>L/L</sup> mice (Hameyer et al., 2007). These mice were generated with above mating scheme. All the mice were cared and monitored according to DFCI animal research facility guideline.

### Neurosphere Formation

Primary neurospheres were dissociated and seeded at 2 cells/ $\mu$ l density in multiwell plates. After 7–10 days, cultures were monitored for the formation of neurospheres. Alternatively, single cells were sorted into individual well on 384-well plate on Dako MoFlo high-speed cell sorter and cultured for 3 weeks. Neurospheres were transferred to culture wells coated with poly-L-ornithine (15  $\mu$ g/ml) and fibronectin (1  $\mu$ g/ml) and differentiated in 1% FBS in neurobasal media to measure their multipotentiality. Quantification of neurosphere numbers and diameters were performed by bright-field microscopy coupled with an in-house semiautomated segmentation algorithm generated with MATLAB software (The Mathworks, Natick, MA).

### Intracellular ROS Measurement

FoxO WT and null NSCs were incubated with NAC (1 mM) or H<sub>2</sub>O<sub>2</sub> (100  $\mu$ M) for entire culture period or 30 min, respectively. DCF-DA (25  $\mu$ M, Molecular Probes) was added to cultures and incubated for an additional 30 min at 37°C. Levels of fluorescent adduct was measured by flow cytometry with excitation at 488 nm.

### Measuring NSC Apoptosis and Proliferation

For analysis of apoptosis, NSCs were fixed with 4% paraformaldehyde, permeabilized, and stained for cleaved caspase-3 (Calbiochem). For BrdU incorporation, BrdU-treated (6  $\mu$ g/ml, 2 hr) cells were fixed and treated with 2N HCl for 15 min and permeabilized with 0.2% Triton X-100 followed by primary mouse anti-BrdU (1:200, Roche, Bu20a) incubation followed by secondary antibody labeling as below.

### In Vivo Administration of NAC

NAC (500 mg/kg, Sigma) and BSO (5 mmol/kg, Sigma) were dissolved in PBS and injected subcutaneously for 5 days starting from P3. On day 4 (P7), mice were intraperitoneally injected with 1 mg of BrdU. 24 hr after BrdU injection, mice were sacrificed and analyzed.

### Reporter Assay for Canonical Wnt Pathway

500 ng of reporter construct TOPFLASH (kindly provided by Randall Moon) was transfected into  $1 \times 10^6$  FoxO WT and null NSCs with Lipofectamine 2000. 50 ng of pTk-renilla control vector was cotransfected as an internal control. 50 ng/ml of recombinant Wnt3a or Wnt5 (R&D systems) was added to media and 48 hr after transfection cells were lysed and analyzed for luciferase with the Dual Luciferase Reporter Assay system (Promega) according to the manufacturer's instructions.

### Quantitation of Neurons and Glia

Brains sections from four littermates WT and FoxO-null mice (P10) were stained for NeuN and S100. Positive cells with the cerebral cortex region dorsal to the hippocampal formation were scored.

### Laser Scanning Analysis for the Quantitation of IHC

Laser scanning cytometry quantification of DCX and Sox-2 was performed by iCys Research Imaging Cytometer (Compucyte) as described early (Gorczyca et al., 2001) with a few following modifications. Counts of DCX<sup>+</sup> or Sox2<sup>+</sup> (DAB positive) were carried out within the subventricular zones that were predefined by a certified pathologist with the H&E-stained brain architecture. The target number for each sample was approximately 500 cells counted. The size of ventricular area and thickness of corpus callosum and cortex was measured by ImageJ software. The paired t test was used to compare the differences between wild-type and FoxO-null brains.

### Statistical Analysis

All the data were analyzed by unpaired two-tail Student's t test unless specified in the figure legend.

### ACCESSION NUMBERS

The microarray data have been deposited in the GEO database with accession number GSE18308.

### SUPPLEMENTAL DATA

Supplemental Data include Supplemental Experimental Procedures, eight figures, and three tables and can be found with this article online at [http://www.cell.com/cell-stem-cell/supplemental/S1934-5909\(09\)00509-8](http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00509-8).

### ACKNOWLEDGMENTS

J.-h.P. is Damon Runyon Fellow was supported by the Damon Runyon Cancer Research Foundation (DRG 1900-06). Grant support includes the Claudia Adam Barr Foundation (J.-h.P.), ACS fellowship (F.M.), ABTA fellowship (H.Y.), Ellison Medical Foundation (R.A.D.), and 5P01CA95616 (R.A.D., K.L.L., L.C.). R.A.D. is an American Cancer Society Research Professor and supported by the Robert A. and Renee E. Belfer Foundation Institute for Applied Cancer Science. We thank D. Pellman and S. Yoshida for the deconvolution microscope use and advice, R. Maser for MSCV-puro-v5 gateway vector, W. Hahn for shRNA constructs, and J. Ling for technical assistance.

Received: March 26, 2009

Revised: July 1, 2009

Accepted: September 28, 2009

Published: November 5, 2009

### REFERENCES

- Alvarez, B., Martinez, A.C., Burgering, B.M., and Carrera, A.C. (2001). Fork-head transcription factors contribute to execution of the mitotic programme in mammals. *Nature* 413, 744–747.
- Battista, D., Ferrari, C.C., Gage, F.H., and Pitossi, F.J. (2006). Neurogenic niche modulation by activated microglia: Transforming growth factor beta increases neurogenesis in the adult dentate gyrus. *Eur. J. Neurosci.* 23, 83–93.
- Birkenkamp, K.U., Essafi, A., van der Vos, K.E., da Costa, M., Hui, R.C., Holstege, F., Koenderman, L., Lam, E.W., and Coffey, P.J. (2007). FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. *J. Biol. Chem.* 282, 2211–2220.
- Bond, J., Roberts, E., Mochida, G.H., Hampshire, D.J., Scott, S., Askham, J.M., Springell, K., Mahadevan, M., Crow, Y.J., Markham, A.F., et al. (2002). ASPM is a major determinant of cerebral cortical size. *Nat. Genet.* 32, 316–320.
- Brack, A.S., Conboy, M.J., Roy, S., Lee, M., Kuo, C.J., Keller, C., and Rando, T.A. (2007). Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. *Science* 317, 807–810.
- Cheng, T., Rodrigues, N., Dombkowski, D., Stier, S., and Scadden, D.T. (2000a). Stem cell repopulation efficiency but not pool size is governed by p27(kip1). *Nat. Med.* 6, 1235–1240.
- Cheng, T., Rodrigues, N., Shen, H., Yang, Y., Dombkowski, D., Sykes, M., and Scadden, D.T. (2000b). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 287, 1804–1808.
- Doetsch, F., Petreanu, L., Caille, I., Garcia-Verdugo, J.M., and Alvarez-Buylla, A. (2002a). EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. *Neuron* 36, 1021–1034.
- Doetsch, F., Verdugo, J.M., Caille, I., Alvarez-Buylla, A., Chao, M.V., and Casaccia-Bonnel, P. (2002b). Lack of the cell-cycle inhibitor p27Kip1 results in selective increase of transit-amplifying cells for adult neurogenesis. *J. Neurosci.* 22, 2255–2264.



- Fish, J.L., Kosodo, Y., Enard, W., Paabo, S., and Huttner, W.B. (2006). Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. *Proc. Natl. Acad. Sci. USA* **103**, 10438–10443.
- Gan, B., Sahin, E., Jiang, S., Sanchez-Aguilera, A., Scott, K.L., Chin, L., Williams, D.A., Kwiatkowski, D.J., and DePinho, R.A. (2008). mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. *Proc. Natl. Acad. Sci. USA* **105**, 19384–19389.
- Gorczyca, W., Deptala, A., Bedner, E., Li, X., Melamed, M.R., and Darzynkiewicz, Z. (2001). Analysis of human tumors by laser scanning cytometry. *Methods Cell Biol.* **64**, 421–443.
- Greer, E.L., and Brunet, A. (2005). FOXO transcription factors at the interface between longevity and tumor suppression. *Oncogene* **24**, 7410–7425.
- Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. (2001). Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. *Science* **294**, 2186–2189.
- Groszer, M., Erickson, R., Scripture-Adams, D.D., Dougherty, J.D., Le Belle, J., Zack, J.A., Geschwind, D.H., Liu, X., Kornblum, H.I., and Wu, H. (2006). PTEN negatively regulates neural stem cell self-renewal by modulating G0–G1 cell cycle entry. *Proc. Natl. Acad. Sci. USA* **103**, 111–116.
- Hameyer, D., Loonstra, A., Eshkind, L., Schmitt, S., Antunes, C., Groen, A., Bindels, E., Jonkers, J., Krimpenfort, P., Meuwissen, R., et al. (2007). Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. *Physiol. Genomics* **31**, 32–41.
- Hoekman, M.F., Jacobs, F.M., Smidt, M.P., and Burbach, J.P. (2006). Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. *Gene Expr. Patterns* **6**, 134–140.
- Horvath, S., Zhang, B., Carlson, M., Lu, K.V., Zhu, S., Feliciano, R.M., Laurance, M.F., Zhao, W., Qi, S., Chen, Z., et al. (2006). Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. *Proc. Natl. Acad. Sci. USA* **103**, 17402–17407.
- Hosaka, T., Biggs, W.H., 3rd, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., and Arden, K.C. (2004). Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. *Proc. Natl. Acad. Sci. USA* **101**, 2975–2980.
- Hu, P., Geles, K.G., Paik, J.H., DePinho, R.A., and Tjian, R. (2008). Codependent activators direct myoblast-specific MyoD transcription. *Dev. Cell* **15**, 534–546.
- Imayoshi, I., Sakamoto, M., Ohtsuka, T., Takao, K., Miyakawa, T., Yamaguchi, M., Mori, K., Ikeda, T., Itohara, S., and Kageyama, R. (2008). Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. *Nat. Neurosci.* **11**, 1153–1161.
- Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004). Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nature* **431**, 997–1002.
- Ito, K., Hirao, A., Arai, F., Takubo, K., Matsuoka, S., Miyamoto, K., Ohmura, M., Naka, K., Hosokawa, K., Ikeda, Y., et al. (2006). Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat. Med.* **12**, 446–451.
- Jin, K., Sun, Y., Xie, L., Bateur, S., Mao, X.O., Smelick, C., Logvinova, A., and Greenberg, D.A. (2003). Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. *Aging Cell* **2**, 175–183.
- Kippin, T.E., Martens, D.J., and van der Kooy, D. (2005). p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. *Genes Dev.* **19**, 756–767.
- Kitamura, T., Kitamura, Y.I., Funahashi, Y., Shawber, C.J., Castrillon, D.H., Kollipara, R., DePinho, R.A., Kitajewski, J., and Accili, D. (2007). A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. *J. Clin. Invest.* **117**, 2477–2485.
- Kozar, K., Ciemerych, M.A., Rebel, V.I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R.T., et al. (2004). Mouse development and cell proliferation in the absence of D-cyclins. *Cell* **118**, 477–491.
- Krishnamurthy, J., Ramsey, M.R., Ligon, K.L., Torrice, C., Koh, A., Bonner-Weir, S., and Sharpless, N.E. (2006). p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature* **443**, 453–457.
- Lim, D., Huang, Y.C., Swigut, T., Mirick, A.L., Garcia-Verdugo, J.M., Wysocka, J., Ernst, P., and Alvarez-Buylla, A. (2009). Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. *Nature* **58**, 529–533.
- Liu, H., Fergusson, M.M., Castilho, R.M., Liu, J., Cao, L., Chen, J., Malide, D., Rovira, I.L., Schimel, D., Kuo, C.J., et al. (2007). Augmented Wnt signaling in a mammalian model of accelerated aging. *Science* **317**, 803–806.
- Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., Dubus, P., and Barbacid, M. (2004). Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell* **118**, 493–504.
- Miyamoto, K., Araki, K.Y., Naka, K., Arai, F., Takubo, K., Yamazaki, S., Matsuoka, S., Miyamoto, T., Ito, K., Ohmura, M., et al. (2007). Foxo3a is essential for maintenance of the hematopoietic stem cell pool. *Cell Stem Cell* **1**, 101–112.
- Molofsky, A.V., Slutsky, S.G., Joseph, N.M., He, S., Pardal, R., Krishnamurthy, J., Sharpless, N.E., and Morrison, S.J. (2006). Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. *Nature* **443**, 448–452.
- Morshead, C.M., Reynolds, B.A., Craig, C.G., McBurney, M.W., Staines, W.A., Morassutti, D., Weiss, S., and van der Kooy, D. (1994). Neural stem cells in the adult mammalian forebrain: A relatively quiescent subpopulation of subependymal cells. *Neuron* **13**, 1071–1082.
- Paik, J.H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J.W., Carrasco, D.R., et al. (2007). FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. *Cell* **128**, 309–323.
- Paling, N.R., Wheadon, H., Bone, H.K., and Welham, M.J. (2004). Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. *J. Biol. Chem.* **279**, 48063–48070.
- Païma, V., Lim, D.A., Dahmane, N., Sanchez, P., Brionne, T.C., Herzberg, C.D., Gitton, Y., Carleton, A., Alvarez-Buylla, A., and Ruiz i Altaba, A. (2005). Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. *Development* **132**, 335–344.
- Puig, O., Marr, M.T., Ruhf, M.L., and Tjian, R. (2003). Control of cell number by *Drosophila* FOXO: downstream and feedback regulation of the insulin receptor pathway. *Genes Dev.* **17**, 2006–2020.
- Renault, V.M., Rafalski, V.A., Morgan, A.A., Salih, D.A.M., Brett, J.O., Webb, A.E., Villeda, S.A., Thekkat, P.U., Guillerey, C., Denko, N.C., et al. (2009). FoxO3 regulates neural stem cell homeostasis. *Cell Stem Cell* **5**, this issue, 527–539.
- Reya, T., Duncan, A.W., Ailles, L., Domen, J., Scherer, D.C., Willert, K., Hintz, L., Nusse, R., and Weissman, I.L. (2003). A role for Wnt signalling in self-renewal of haematopoietic stem cells. *Nature* **423**, 409–414.
- Schmidt, M., Fernandez de Mattos, S., van der Horst, A., Klompaker, R., Kops, G.J., Lam, E.W., Burgering, B.M., and Medema, R.H. (2002). Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. *Mol. Cell. Biol.* **22**, 7842–7852.
- Seoane, J., Le, H.V., Shen, L., Anderson, S.A., and Massague, J. (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. *Cell* **117**, 211–223.
- Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**, 70–71.
- Tothova, Z., Kollipara, R., Huntly, B.J., Lee, B.H., Castrillon, D.H., Cullen, D.E., McDowell, E.P., Lazo-Kallanian, S., Williams, I.R., Sears, C., et al. (2007). FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* **128**, 325–339.
- Wang, F., Nguyen, M., Qin, F.X., and Tong, Q. (2007). SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. *Aging Cell* **6**, 505–514.

Yilmaz, O.H., Valdez, R., Theisen, B.K., Guo, W., Ferguson, D.O., Wu, H., and Morrison, S.J. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* 441, 475–482.

Yuan, Y., Shen, H., Franklin, D.S., Scadden, D.T., and Cheng, T. (2004). In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. *Nat. Cell Biol.* 6, 436–442.

Zhao, C., Deng, W., and Gage, F.H. (2008). Mechanisms and functional implications of adult neurogenesis. *Cell* 132, 645–660.

Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.J., Perry, S.R., Tonon, G., Chu, G.C., Ding, Z., et al. (2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature* 455, 1129–1133.

Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K., and Messing, A. (2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. *Genesis* 31, 85–94.